Western Blot (WB)
(Expression analysis of CYP1B1. Anti-CYP1B1 antibody (11-1003) was used at 4 µg/ml on A549 lysate.)
Rabbit anti-Human CYP1B1 Polyclonal Antibody | anti-CYP1B1 antibody
CYP1B1 Polyclonal Antibody
Western Blot (WB)
(Expression analysis of CYP1B1. Anti-CYP1B1 antibody (11-1003) was used at 4 µg/ml on A549 lysate.)
Western Blot (WB)
(Expression analysis of CYP1B1. Anti-CYP1B1 antibody (11-1003) was used at 4 µg/ml on A549 lysate.)
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The enzyme encoded by this gene localizes to the endoplasmic reticulum and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol. Mutations in this gene have been associated with primary congenital glaucoma; therefore it is thought that the enzyme also metabolizes a signaling molecule involved in eye development, possibly a steroid. [provided by RefSeq, Jul 2008]
Uniprot Description
CYP1B1: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Defects in CYP1B1 are the cause of primary congenital glaucoma type 3A (GLC3A). GLC3A is an autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor. Defects in CYP1B1 are a cause of primary open angle glaucoma (POAG). POAG is a complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. The disease is asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes. Defects in CYP1B1 are a cause of Peters anomaly (PAN). Peters anomaly is a congenital defect of the anterior chamber of the eye. Belongs to the cytochrome P450 family.
Protein type: Oxidoreductase; Amino Acid Metabolism - tryptophan; Xenobiotic Metabolism - metabolism by cytochrome P450; EC 1.14.14.1
Chromosomal Location of Human Ortholog: 2p22.2
Cellular Component: endoplasmic reticulum membrane; mitochondrion
Molecular Function: iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; heme binding; oxygen binding; monooxygenase activity
Biological Process: steroid metabolic process; estrogen metabolic process; retinal metabolic process; collagen fibril organization; positive regulation of apoptosis; response to toxin; positive regulation of JAK-STAT cascade; negative regulation of cell proliferation; visual perception; retinol metabolic process; arachidonic acid metabolic process; angiogenesis; cell adhesion; nitric oxide biosynthetic process; negative regulation of cell adhesion mediated by integrin; negative regulation of cell migration; epoxygenase P450 pathway; positive regulation of angiogenesis; inhibition of NF-kappaB transcription factor; toxin metabolic process; xenobiotic metabolic process; aromatic compound metabolic process; endothelial cell migration; blood vessel morphogenesis; membrane lipid catabolic process; sterol metabolic process; induction of apoptosis by oxidative stress
Disease: Peters Anomaly; Glaucoma 3, Primary Congenital, A; Glaucoma 3, Primary Infantile, B
Research Articles on CYP1B1
Similar Products
Product Notes
The CYP1B1 cyp1b1 (Catalog #AAA668135) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The CYP1B1 Polyclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CYP1B1 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB). Western Blot: 2-4 µg/ml. Researchers should empirically determine the suitability of the CYP1B1 cyp1b1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CYP1B1, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
